Concepedia

Publication | Open Access

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

DOIFull Paper Access

10

Citations

11

References

2019

Year

Bruce A. Perkins, Nima Soleymanlou, Julio Rosenstock, Jay S. Skyler, Lori M. Laffel, Karl‐Heinz Liesenfeld, Dietmar Neubacher, Matthew M. Riggs, Curtis Johnston, Rena J. Eudy‐Byrne,
Diabetes Obesity and Metabolism

Abstract

The HbA1c benefit of low-dose empagliflozin directly observed in the EASE-3 trial was confirmed by two modelling and simulation approaches.

References

YearCitations

Page 1